Pharmaceuticals, Biotechnology and Life Sciences
Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple medically vulnerable…
BEVERLY, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) — Thrive Bioscience, Inc., a Boston-based manufacturer of instruments for advanced imaging, analytics,…
Formycon AG and its commercialization partner Fresenius Kabi jointly said Monday that the U.S. Food and Drug Administration (FDA) has approved FYB202/OtulfiTM1 (ustekinumab-aauz), a biosimilar to Stelara, for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis, the third Formycon biosimilar successfully approved by the FDA.
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
Renowned Biotech Leader to Contribute Expertise in Neuroscience and Therapeutics DevelopmentNEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) — Klotho Neurosciences,…
/ Not for distribution to U.S. news wire services or for dissemination in the United States / VANCOUVER, British Columbia,…
Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by…
CARLSBAD, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer, and…
– Acoramidis treatment led to a highly significant reduction in all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at Month…
45 percent reduction in risk of death achieved with cilta-cel versus standard therapies after three-year follow-up in landmark CARTITUDE-4 study1…